1. Home
  2. KPTI vs STIM Comparison

KPTI vs STIM Comparison

Compare KPTI & STIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KPTI
  • STIM
  • Stock Information
  • Founded
  • KPTI 2008
  • STIM 2003
  • Country
  • KPTI United States
  • STIM United States
  • Employees
  • KPTI 325
  • STIM N/A
  • Industry
  • KPTI Biotechnology: Pharmaceutical Preparations
  • STIM Medical/Dental Instruments
  • Sector
  • KPTI Health Care
  • STIM Health Care
  • Exchange
  • KPTI Nasdaq
  • STIM Nasdaq
  • Market Cap
  • KPTI 81.1M
  • STIM 192.0M
  • IPO Year
  • KPTI 2013
  • STIM 2018
  • Fundamental
  • Price
  • KPTI $0.66
  • STIM $3.56
  • Analyst Decision
  • KPTI Strong Buy
  • STIM Buy
  • Analyst Count
  • KPTI 4
  • STIM 4
  • Target Price
  • KPTI $5.00
  • STIM $4.67
  • AVG Volume (30 Days)
  • KPTI 671.2K
  • STIM 1.4M
  • Earning Date
  • KPTI 02-27-2025
  • STIM 03-04-2025
  • Dividend Yield
  • KPTI N/A
  • STIM N/A
  • EPS Growth
  • KPTI N/A
  • STIM N/A
  • EPS
  • KPTI N/A
  • STIM N/A
  • Revenue
  • KPTI $148,442,000.00
  • STIM $72,711,000.00
  • Revenue This Year
  • KPTI $5.47
  • STIM $1.97
  • Revenue Next Year
  • KPTI $6.33
  • STIM $7.96
  • P/E Ratio
  • KPTI N/A
  • STIM N/A
  • Revenue Growth
  • KPTI 1.77
  • STIM 5.03
  • 52 Week Low
  • KPTI $0.58
  • STIM $0.52
  • 52 Week High
  • KPTI $1.70
  • STIM $5.07
  • Technical
  • Relative Strength Index (RSI)
  • KPTI 46.51
  • STIM 73.20
  • Support Level
  • KPTI $0.60
  • STIM $2.88
  • Resistance Level
  • KPTI $0.70
  • STIM $3.60
  • Average True Range (ATR)
  • KPTI 0.05
  • STIM 0.38
  • MACD
  • KPTI -0.00
  • STIM 0.06
  • Stochastic Oscillator
  • KPTI 46.61
  • STIM 91.39

About KPTI Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

About STIM Neuronetics Inc.

Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulations, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advanced Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of existing treatment options.

Share on Social Networks: